![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Jan123 (naltrexone) is being developed for the treatment of Complex Regional Pain Syndrome (CRPS), an indication that causes severe, chronic pain generally affecting the arms or legs.
Lead Product(s): Naltrexone
Therapeutic Area: Neurology Product Name: JAN123
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: JanOne
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition January 10, 2023